Sanofi has acquired Zentiva Slovakia
The public shareholders of Zentiva Slovakia have sold approximately a 3% stake in the company to Sanofi, in a share buyback transaction. Financial details have not been disclosed.
Sanofi is a global and diversified healthcare leader which researches, develops and distributes therapeutic solutions focused on patients’ needs. The company has core strengths in healthcare, with six growth platforms: emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products and animal health.
Zentiva Slovakia is a producer of pharmaceutical products. Its product range consists of approximately 270 references in 500 pharmaceutical presentations, of which 180 are bound by prescription and 100 are OTC preparations or food supplements. The company focuses on the treatment of cardiovascular disorders, inflammatory conditions, pain, infections and diseases of the central nervous system and the gastrointestinal and urinary tracts. It also offers over-the-counter medicines and dietary supplements. It offers a range of therapeutic areas. In addition to generic drugs, Zentiva Slovakia also produces cosmetics and pharmaceutical substances.
Oaklins' team in Slovakia acted as financial advisor to the buyer in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more